SCHEMBL4353820

SCHEMBL4353820

Cn1cnc2nc(-c3ccc(F)cc3)n(NCc3ccc(Br)cc3)c(=O)c21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.38
TRPA1 O75762 7/20 0.38
MAPT P10636 2/20 0.35
NPSR1 Q6W5P4 1/20 0.35
CES2 O00748 1/20 0.35
TP53 P04637 1/20 0.35
IKBKB O14920 4/20 0.34
CHUK O15111 4/20 0.34
GAA P10253 2/20 0.34
MGAM O43451 1/20 0.34
SI P14410 1/20 0.34
MGAM2 Q2M2H8 1/20 0.34
KDM4E B2RXH2 1/20 0.34
MEN1 O00255 1/20 0.34
ALDH1A1 P00352 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
HPGD P15428 1/20 0.34
ALOX12 P18054 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4357822 0.90 TRPA1 (0.40) SMN1; SMN2TRPA1MAPTCES2GAA
SCHEMBL4345893 0.80 SMN1; SMN2 (0.42) SMN1; SMN2MAPTNPSR1CES2TP53
SCHEMBL4199192 0.79 SMN1; SMN2 (0.48) SMN1; SMN2MAPTNPSR1CES2TP53
SCHEMBL4236185 0.74 SMN1; SMN2 (0.67) SMN1; SMN2MAPTNPSR1GAAMEN1
SCHEMBL4242353 0.74 SMN1; SMN2 (0.50) SMN1; SMN2MAPTNPSR1GAAMEN1
SCHEMBL4241365 0.74 SMN1; SMN2 (0.48) SMN1; SMN2MAPTNPSR1CES2GAA
SCHEMBL4195763 0.74 SMN1; SMN2 (0.48) SMN1; SMN2MAPTNPSR1GAAKDM4E
SCHEMBL4233963 0.74 SMN1; SMN2 (0.48) SMN1; SMN2MAPTNPSR1TP53GAA
SCHEMBL4201369 0.73 SMN1; SMN2 (0.44) SMN1; SMN2MAPTNPSR1CES2TP53
SCHEMBL4735977 0.73 SMN1; SMN2 (0.48) SMN1; SMN2MAPTNPSR1TP53GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-04-23 US disclosed
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-04-23 US disclosed
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-04-23 US disclosed
WO-2009026241-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 GPBAR1, GPR119, GRK5 SMN1; SMN2 3183/4885TRPA1 670/4885MAPT 4164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.